Stay updated on Daratumumab & DLI for Relapsed AML Clinical Trial
Sign up to get notified when there's something new on the Daratumumab & DLI for Relapsed AML Clinical Trial page.

Latest updates to the Daratumumab & DLI for Relapsed AML Clinical Trial page
- Check5 days agoChange DetectedThe page now displays Revision: v3.6.3, replacing v3.6.0, indicating an internal update to the page framework; no study content or visible details appear to be affected.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe page adds new user guidance sections (How to Read a Study Record, Common Questions, How to Join a Study) and updates the Intervention/Treatment label formatting, while also displaying a new revision tag (v3.6.0) and noting that recruitment is no longer open.SummaryDifference0.5%

- Check26 days agoChange DetectedThe revision tag on the page was updated from v3.5.4 to v3.5.5. This indicates a minor deployment update and does not modify the study details or other user-facing content.SummaryDifference0.1%

- Check47 days agoChange DetectedThe page's revision tag was updated to v3.5.4, indicating a new software revision was applied. The previous revision v3.5.3 was removed.SummaryDifference0.1%

- Check69 days agoChange DetectedThe page’s release/version marker was updated from “Revision: v3.5.2” to “Revision: v3.5.3,” indicating a ClinicalTrials.gov site revision without changing the underlying study details.SummaryDifference0.1%

- Check76 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2; no user-facing content changes are evident.SummaryDifference0.1%

Stay in the know with updates to Daratumumab & DLI for Relapsed AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab & DLI for Relapsed AML Clinical Trial page.